ALFA FinderNSE filing, NSE: GUFICBIO. Summary written from the filing by ALFA Finder's alert engine.
Gufic BioSciences Ltd: key numbers
- Share price
- ₹470.00
- Market cap
- ₹4,713 Cr
- Revenue (annual)
- ₹944.0 Cr
- Net profit (annual)
- ₹64.21 Cr
- P/E (TTM)
- 64.2×Sector 43.8×
- Promoter holding
- 72.50%+0.00% QoQ
- FII holding
- 0.44%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Gufic BioSciences Ltd
All →Gufic BioSciences Board Meeting Date
Gufic Biosciences gives notice of a board meeting on 14 November 2026 to consider unaudited standalone and consolidated quarterly results. The filing carries no financial figures or business decision.
Gufic BioSciences Legal & Regulatory
Gufic Biosciences' tax dispute moved after the ITAT remanded matters to the Assessing Officer. The residual Rs. 11.76 lakh demand will be redetermined in fresh assessment.
- Value
- ₹0.12 Cr
Gufic BioSciences Legal & Regulatory
Gufic Biosciences disclosed an ITAT Mumbai order for AY 2023-24 that set aside the CIT(A) findings and restored the matter to the Assessing Officer. No demand arises from the order, and the tax liability will be determined after fresh assessment.
Gufic BioSciences Business Update
Gufic Biosciences reported a USFDA pre-approval inspection at its Indore facility, concluding October 23, 2026. The inspection produced three Form 483 observations, now being addressed.
Gufic BioSciences Other Announcement
Gufic Biosciences Ltd filed its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI regulations.
Gufic BioSciences Legal & Regulatory
Gufic Biosciences received a favorable appellate order from the Income Tax Commissioner. This order deletes an income tax demand of Rs. 4.33 Crore.
- Value
- ₹4.33 Cr
Other other announcement announcements
All →Innovision Other Announcement
Innovision changed its accounting estimate for NHAI toll fee recognition from straight-line to traffic-based, effective 1 July 2026. It alters expense timing, not total fees.
Raaj Medisafe India Other Announcement
Raaj Medisafe filed its Reg 32 statement on preferential issue proceeds for the quarter ended September 2026. No deviation in fund use is reported.
Italian Edibles Other Announcement
Italian Edibles reports no IPO fund deviation for the half year to September 2026. Project cost rose to Rs 2,300 lakhs; IPO proceeds temporarily shifted across sub-heads.
Porwal Auto Components Other Announcement
Porwal Auto's statement confirms no deviation in preferential issue fund use for the quarter ended September 30, 2026. The filing reports Rs 577.03 lakh utilised.
DCM Other Announcement
DCM Limited named three officials, including the MD, authorised to determine materiality of events under Regulation 30(5). The authorisation takes effect from 16 November 2026.
Systematix Corporate Services Other Announcement
Systematix filed a monitoring agency report on its preferential issue proceeds for the quarter ended September 2026. The report found no deviation from offer objects.